Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy

Shandiz Shahbazi, Cody J. Peer, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

3 Scopus citations
Original languageEnglish
Pages (from-to)1117-1119
Number of pages3
JournalCancer Biology and Therapy
Volume15
Issue number9
DOIs
StatePublished - Sep 2014
Externally publishedYes

Keywords

  • Burkitt lymphoma
  • Epoch regimen
  • Low-intensity therapy

Fingerprint

Dive into the research topics of 'Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy'. Together they form a unique fingerprint.

Cite this